CN114222753B - 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 - Google Patents
一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 Download PDFInfo
- Publication number
- CN114222753B CN114222753B CN202080057168.XA CN202080057168A CN114222753B CN 114222753 B CN114222753 B CN 114222753B CN 202080057168 A CN202080057168 A CN 202080057168A CN 114222753 B CN114222753 B CN 114222753B
- Authority
- CN
- China
- Prior art keywords
- neuroblastoma
- leu
- gly
- polypeptide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010089778X | 2020-02-13 | ||
CN202010089778.XA CN113244370A (zh) | 2020-02-13 | 2020-02-13 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
PCT/CN2020/075599 WO2021159546A1 (zh) | 2020-02-13 | 2020-02-17 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114222753A CN114222753A (zh) | 2022-03-22 |
CN114222753B true CN114222753B (zh) | 2022-10-04 |
Family
ID=77219776
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010089778.XA Pending CN113244370A (zh) | 2020-02-13 | 2020-02-13 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
CN202080057168.XA Active CN114222753B (zh) | 2020-02-13 | 2020-02-17 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010089778.XA Pending CN113244370A (zh) | 2020-02-13 | 2020-02-13 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
Country Status (3)
Country | Link |
---|---|
US (2) | US20230181696A1 (zh) |
CN (2) | CN113244370A (zh) |
WO (1) | WO2021159546A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530199A (zh) * | 2014-11-18 | 2015-04-22 | 哈尔滨医科大学 | 一种抗肿瘤多肽及其制备方法和应用 |
WO2017016430A1 (zh) * | 2015-07-27 | 2017-02-02 | 上海吉贝医药科技有限公司 | 一种肿瘤抑制肽 |
CN107778362A (zh) * | 2017-11-22 | 2018-03-09 | 哈尔滨医科大学 | 一种用于抑制口腔鳞状细胞癌迁移和侵袭能力的多肽及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001037871A1 (en) * | 1999-11-22 | 2001-05-31 | Childrens Hospital Los Angeles Research Institute | Method of treating neuroblastoma |
-
2020
- 2020-02-13 CN CN202010089778.XA patent/CN113244370A/zh active Pending
- 2020-02-17 WO PCT/CN2020/075599 patent/WO2021159546A1/zh active Application Filing
- 2020-02-17 US US17/799,552 patent/US20230181696A1/en not_active Abandoned
- 2020-02-17 CN CN202080057168.XA patent/CN114222753B/zh active Active
-
2024
- 2024-03-07 US US18/598,527 patent/US20240207367A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530199A (zh) * | 2014-11-18 | 2015-04-22 | 哈尔滨医科大学 | 一种抗肿瘤多肽及其制备方法和应用 |
WO2017016430A1 (zh) * | 2015-07-27 | 2017-02-02 | 上海吉贝医药科技有限公司 | 一种肿瘤抑制肽 |
CN107778362A (zh) * | 2017-11-22 | 2018-03-09 | 哈尔滨医科大学 | 一种用于抑制口腔鳞状细胞癌迁移和侵袭能力的多肽及其用途 |
Non-Patent Citations (4)
Title |
---|
A LC-MS/MS method to monitor the concentration of HYD-PEP06, a RGD-modified Endostar mimetic peptide in rat blood;Xiaona Dong et al;《Journal of Chromatography B》;20180815;第1092卷(第15期);摘要,第296页 * |
Continuous Versus Intermittent Administration of Human Endostatin in Xenografted Human Neuroblastoma;Minoru Kuroiwa et al;《Journal of Pediatric Surgery》;20031031;第38卷(第10期);第1499-1505页 * |
Effects of recombinant human endostatin on a human neuroblastoma xenograft;Minoru Kuroiwa et al;《International Jouranl of Molecular Medicine》;20011231;第8卷;第391-396页 * |
Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft modelLack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model;Emmanuel Jouanneau et al;《Journal of Neuro-Oncology》;20011231;第51卷(第11期);第11-18页 * |
Also Published As
Publication number | Publication date |
---|---|
US20240207367A1 (en) | 2024-06-27 |
CN113244370A (zh) | 2021-08-13 |
WO2021159546A1 (zh) | 2021-08-19 |
CN114222753A (zh) | 2022-03-22 |
US20230181696A1 (en) | 2023-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111803493A (zh) | 马来酸替加色罗在制备抗肿瘤药物中的应用 | |
EP3320901B1 (en) | Dimethylaminomicheliolide for use in the treatment of pulmonary fibrosis | |
CN114222753B (zh) | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 | |
CN114949000B (zh) | 麝香提取物及其增强car-t细胞疗效的应用 | |
CN114222580B (zh) | 一种预防和/或治疗卵巢癌的多肽药物及其用途 | |
CN101679499B (zh) | 抗肿瘤药物、药剂、组合物及其用途 | |
CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
CN111803484B (zh) | 奥替溴铵在制备抗肿瘤药物中的应用 | |
KR20210076863A (ko) | 니클로사마이드를 포함하는 섬유증의 예방 및 치료용 조성물 | |
US10646553B2 (en) | Use of recombinant human calcineurin B subunit | |
CN1090491A (zh) | 预防及治疗脓毒症的方法 | |
CN111803482B (zh) | 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物 | |
CN113304249B (zh) | 胸腺素β4在制备肺纤维化合并肺癌病治疗药物中的应用 | |
CN111574590B (zh) | 一种具有抗肿瘤功能的多肽及其应用 | |
CN110856716A (zh) | 一种化合物及其药物组合物在肾脏纤维化防治中的应用 | |
WO2024026694A1 (zh) | 麝香提取物及其增强car-t细胞疗效的应用 | |
KR100674604B1 (ko) | 싸이클릭다이펩타이드를 주성분으로 하는 방사선 보호제 | |
RU2212240C1 (ru) | Способ лечения туберкулеза | |
CN118304412A (zh) | 一种特异性阻断acvr1c与grem1结合的多肽及其应用 | |
CN118766907A (zh) | 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途 | |
US20210038567A1 (en) | Method of inhibiting cancer metastasis | |
RU2211035C1 (ru) | Противотуберкулезный препарат | |
JP2024502336A (ja) | がんを治療するための医薬組成物、その製造方法及び使用 | |
CN118045193A (zh) | 组合物、纳米颗粒、药物及其应用 | |
CN117653645A (zh) | 仙茅苷在防治椎间盘退变中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Xinchun Inventor after: Zhao Jinlong Inventor after: Yang Baofeng Inventor after: Yuan Ye Inventor after: Liu Yu Inventor after: Wang Zhun Inventor before: Yang Baofeng Inventor before: Yang Xinchun Inventor before: Zhao Jinlong Inventor before: Yuan Ye Inventor before: Liu Yu Inventor before: Wang Zhun |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |